VIRTTU Biologics to Present at The Association of Cancer Immunotherapy (CIMT) Conference 2016 in Mainz, Germany
6th May 2016: Virttu Biologics is pleased to announce that it will be presenting 3 posters, one of which was selected for oral presentation at the 14th CIMT annual meeting, 10-12th May 2016 in Mainz, Germany. The posters will be presented by Virttu CSO, Dr Joe Conner in association with our close collaborator, Professor Tim Cripe (Nationwide Children's Hospital, Columbus, Ohio, USA) and the talk will be presented by Professor Cripe.
The presentations will describe interim results from Virttu's ongoing sponsored clinical trial involving intrapleural administration of their oncolytic immunotherapeutic SEPREHVIR® (HSV1716) in mesothelioma patients (NCT01721018) and preclinical data of SEPREHVIR in combination with immune checkpoint inhibitors and CAR T cells in solid tumors.
On Tuesday 10th May 2016, Dr Conner will present his poster "Immune responses following intrapleural administration of the oncolytic HSV Seprehvir in patients with malignant pleural mesothelioma" in the "Therapeutic Vaccination" session between 15:00-17:30.
On Tuesday 10th May 2016, Prof Cripe will present his poster "Seprehvir, an oncolytic herpes immunotherapeutic, enhances GD2-directed Chimeric Antigen Receptor (CAR) T-cell therapy in GD2-expressing solid tumor xenografts" in the "Cellular Therapy" session between 15:00-17:30.
On Wednesday 11th May, Prof Cripe will present his poster "Seprehvir, an oncolytic herpes viroimmunotherapeutic, enhances therapeutic efficacy of T cell checkpoint inhibition in solid tumors by increasing T cell recruitment and remodeling the immunosuppressive microenvironment" in "Improving Immunity" session between 15:30-18:00. This abstract was selected for oral presentation in the "Improving Immunity" session on May 12 between 10:30-11:45.
The Association for Cancer Immunotherapy (CIMT) is a members-based information and education platform that facilitates the knowledge exchange between academic and industry scientists, physicians and regulatory authorities who research and develop cancer immunotherapies. CIMT's annual meeting is Europe’s largest meeting focused on cancer immunotherapy research and development.
About VIRTTU Biologics
VIRTTU’s lead oncolytic product SEPREHVIR® has been administered to 98 patients ranging from 8 to 84 years with many different types of cancer including brain, melanoma, head and neck cancer, sarcomas, neuroblastoma and mesothelioma (a devastating lung cancer associated with asbestos exposure). In these patients, SEPREHVIR can be administered by the route most suitable for their disease which includes systemic administration by intravenous infusion, direct intratumoral injection, and loco-regional infusion. SEPREHVIR, which the company is interested in partnering for further development, is the first product from an active oncolytic immunotherapy platform technology.
VIRTTU's pipeline also includes new generation oncolytic immunotherapeutics. Our expert scientists have developed novel SEPREHVIR backbones with improved cancer cell killing and enhanced immune stimulation using a proprietary engineering system that streamlines their production.
For further information contact:
- 07/11/2016 Phase I/IIa Mesothelioma Study completes dosing of patients and further clinical updates
- 27/04/2016 VIRTTU Biologics to Present Interim Clinical Study Results at IMIG 2016 in Birmingham, UK
- 19/04/2016 VIRTTU Biologics to Present at Biotrinity 2016 in London
- 09/02/2016 VIRTTU Biologics secures European Patent for next generation oncolytic immunotherapy candidate
- 05/01/2016 VIRTTU Biologics to Present at Biotech Showcase 2016 in San Francisco